Bi-spcific chimeric T cells
OwnerMalcolm K. Brenner, Claudia Rossig +1inventors
InventorsMalcolm K. Brenner, Claudia Rossig, Cliona Rooney
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a bi-specific chimeric T lymphocyte, wherein the lymphocyte comprises both an antigen-specific receptor, such as for Epstein-Barr Virus, and a chimeric receptor, such as for a tumor. In a particular embodiment, administration of an Epstein-Barr Virus T lymphocyte with an 14.G2a-ζ antitumor chimeric receptor is utilized for therapy of neuroblastoma.
Claims42
A T lymphocyte, comprising:
- an antigen-specific receptor, wherein the presence of said antigen-specific receptor leads to increased in vivo survival of said lymphocyte;
- and
- a chimeric receptor.
A cytotoxic T lymphocyte, comprising:
- an Epstein Barr Virus-specific receptor, wherein the presence of said receptor leads to increased in vivo survival of said lymphocyte;
- and
- a 14.G2a-ζ chimeric receptor.
A cytotoxic T lymphocyte, comprising:
- an Epstein Barr Virus-specific receptor, wherein the presence of said receptor leads to increased in vivo survival of said lymphocyte;
- and
- a CD 19 specific chimeric receptor.
A population of cytotoxic T lymphocytes, comprising at least one cytotoxic T lymphocyte having:
- an antigen-specific receptor, wherein the presence of said antigen-specific receptor leads to increased in vivo survival of said lymphocyte;
- and
- a chimeric receptor.
A method of enhancing activity of a chimeric T lymphocyte in an individual, comprising:
- obtaining a T lymphocyte, wherein said T lymphocyte comprises
- an antigen-specific receptor, wherein the presence of said antigen-specific receptor leads to increased in vivo survival of said lymphocyte;
- and
- a chimeric receptor;
- and
- administering said cell to said individual.
A method of treating a disease in an individual, wherein said disease is associated with a pathogen or cell having a first antigen, comprising:
- obtaining a cytotoxic T lymphocyte, wherein said lymphocyte comprises:
- a receptor specific for a second antigen, wherein the presence of said second antigen-specific receptor leads to increased in vivo survival of said lymphocyte;
- and
- a chimeric receptor specific for said first antigen;
- and
- administering said T lymphocyte to said individual.
A method of treating a tumor in an individual, comprising:
- obtaining a cytotoxic T lymphocyte, wherein said lymphocyte comprises:
- an antigen-specific receptor, wherein the presence of said antigen-specific receptor leads to increased in vivo survival of said lymphocyte;
- and
- an antitumor chimeric receptor;
- and
- administering said T lymphocyte to said individual.
A method of preventing cancer or an intractable infection in an individual, wherein said cancer or intractable infection is associated with a pathogen or cell having a first antigen, comprising administering to an individual susceptible to said cancer or intractable infection at least one cytotoxic T lymphocyte, wherein the lymphocyte comprises:
- a receptor specific for a second antigen, wherein the presence of said second antigen-specific receptor leads to increased in vivo survival of said lymphocyte;
- and
- a chimeric receptor specific for said first antigen.
A kit, housed in a suitable container, comprising:
- at least one cytotoxic T lymphocyte in a pharmaceutically acceptable solution, comprising:
- a chimeric receptor specific for said first antigen;
- and
- a receptor specific for a second antigen, wherein the presence of said second antigen-specific receptor leads to increased in vivo survival of said lymphocyte.
Dependencies are inferred from the claim text.